Abbott (ABT)

=== SEC Form 4 — Statement of Changes in Beneficial Ownership === Document Type: 4 Period of Report: 2026-08-25 10b5-1 Pre-arranged Plan: No --- Issuer --- Name: ABBOTT LABORATORIES (ABT) CIK: 0000001800 --- Reporting Owner --- Name: Ford Robert B CIK: 0001612571 Role: Director, Officer (CHAIRMAN AND CEO) --- Non-Derivative Transactions --- [Transaction #1] Security: Common shares without par value Date: 2026-08-25 | Code: M (Exercise of derivative) Shares: +151,869 | Price: $44.40 Total Value: $6,742,983.60 Shares Owned After: 458,330 | Ownership: D (Direct) [Transaction #2] Security: Common shares without par value Date: 2026-08-25 | Code: M (Exercise of derivative) Shares: +246,963 | Price: $59.94 Total Value: $14,802,962.22 Shares Owned After: 705,293 | Ownership: D (Direct) [Transaction #3] Security: Common shares without par value Date: 2026-08-25 | Code: S (Open market sale) Shares: -218,535 | Price: $115.57 Total Value: $25,256,089.95 Shares Owned After: 486,758 | Ownership: D (Direct) Footnotes: [F1] The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.09 to $116.08, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. [Transaction #4] Security: Common shares without par value Date: 2026-08-25 | Code: S (Open market sale) Shares: -180,297 | Price: $116.19 Total Value: $20,948,708.43 Shares Owned After: 306,461 | Ownership: D (Direct) Footnotes: [F2] The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $116.36, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. --- Derivative Transactions --- [Transaction #1] Security: Option (right to buy) Date: 2026-08-25 | Code: M (Exercise of derivative) Shares: -151,869 | Price: $0.00 Exercise Price: $44.40 Exercisable: N/A | Expires: 2027-02-16 Shares Owned After: 0 | Ownership: D (Direct) Footnotes: [F4] Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. [Transaction #2] Security: Option (right to buy) Date: 2026-08-25 | Code: M (Exercise of derivative) Shares: -246,963 | Price: $0.00 Exercise Price: $59.94 Exercisable: N/A | Expires: 2028-02-15 Shares Owned After: 0 | Ownership: D (Direct) Footnotes: [F5] Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. --- Holdings --- [Holding #1] Security: Common shares without par value Ownership: I (Indirect) Footnotes: [F3] Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust. --- Footnotes (Complete Index) --- F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.09 to $116.08, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $116.36, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3: Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust. F4: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. F5: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. --- Signature --- /s/ /s/ Robert B. Ford by Jessica H. Paik, Attorney-in-Fact (2026-08-27)